

ASX RELEASE

13 May 2022

### Amplia Receives Second Ethics Clearance for Phase 2 Trial

- *Second Human Research Ethics Committee approval will facilitate acceleration of recruitment to trial*

Amplia Therapeutics Limited (ASX: ATX) (“Amplia” or the “Company”) is pleased to announce it has received approval from a second Human Research Ethics Committee (HREC) to conduct the Company’s Phase 2 clinical trial of its Focal Adhesion Kinase (FAK) inhibitor, AMP945, in first-line patients with advanced pancreatic cancer.

The Company recently announced (6 April 2022) that it received HREC approval to initiate the trial at sites in NSW, Australia. As noted in that announcement, the Company was awaiting the outcome of a second pending HREC application covering sites in Victoria, Australia. This second approval has now been received, allowing the Company to accelerate recruitment into the trial. No further HREC approvals are pending, and the Company now adjusts its focus to the trial’s execution phase.

Dr John Lambert, Amplia’s CEO and Managing Director noted that “This second HREC approval will allow us to recruit patients more rapidly and begin to generate early efficacy and safety results in people with pancreatic cancer. Our focus is now on timely recruitment and execution of a high-quality trial that will support our future development plans for AMP945 in this very dangerous disease.”

This ASX announcement was approved and authorised for release by the CEO of Amplia Therapeutics.

- End -

#### For Further Information

Dr. John Lambert  
Chief Executive Officer  
[john@ampliatx.com](mailto:john@ampliatx.com)  
[www.ampliatx.com](http://www.ampliatx.com)

#### About Amplia Therapeutics Limited

Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer immunology and Amplia has a particular development focus in pancreatic and ovarian cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF).